Please login to the form below

Not currently logged in

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

US court backs Sanofi/Regeneron in PCSK9 patent dispute with Amgen

US court backs Sanofi/Regeneron in PCSK9 patent dispute with Amgen

patent rights to their PCSK9 inhibitor cholesterol drugs. ... Amgen filed a patent infringement complaint against Sanofi/Regeneron in 2014, claiming that their Praluent (alirocumab) PCSK9 inhibitor infringed on those patients.

Latest news

More from news
Approximately 10 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...